Thrivent Financial for Lutherans
RPRX icon

Thrivent Financial for Lutherans’s Royalty Pharma RPRX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.5M Buy
740,772
+241,605
+48% +$12.6M 0.07% 315
2026
Q1 		$23.9M Buy
499,167
+265,847
+114% +$11.6M 0.05% 397
2025
Q4 		$9.02M Buy
233,320
+22,015
+10% +$840K 0.02% 709
2025
Q3 		$7.46M Sell
211,305
-33,948
-14% -$1.23M 0.01% 714
2025
Q2 		$8.84M Sell
245,253
-230,572
-48% -$7.64M 0.02% 601
2025
Q1 		$14.8M Hold
475,825
– – 0.03% 460
2024
Q4 		$12.1M Buy
475,825
+132,675
+39% +$3.52M 0.02% 599
2024
Q3 		$9.71M Buy
343,150
+168,905
+97% +$4.68M 0.02% 686
2024
Q2 		$4.59M Buy
174,245
+154,408
+778% +$4.28M 0.01% 933
2024
Q1 		$602K Hold
19,837
– – ﹤0.01% 2158
2023
Q4 		$557K Sell
19,837
-1,740
-8% -$47.8K ﹤0.01% 2168
2023
Q3 		$585K Sell
21,577
-2,640
-11% -$78.4K ﹤0.01% 2059
2023
Q2 		$744K Buy
+24,217
New +$820K ﹤0.01% 1986

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans's RPRX Position: Q2 2026 in Review

Thrivent Financial for Lutherans increased its Royalty Pharma (RPRX) stake by 48% in Q2 2026, buying an estimated $12.6M and bringing the position to 740,772 shares worth $41.5M. The position accounts for 0.07% of the portfolio, ranked #315.

Thrivent Financial for Lutherans first reported a position in RPRX in Q2 2023 and has held it in 13 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Thrivent Financial for Lutherans held 740,772 shares of Royalty Pharma worth $41.5M as of Q2 2026.
  • Thrivent Financial for Lutherans bought 241,605 Royalty Pharma shares in Q2 2026, an estimated $12.6M.
  • Royalty Pharma made up 0.07% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #315 holding.
  • Thrivent Financial for Lutherans first reported a position in Royalty Pharma in Q2 2023 and has held it in 13 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.